Optiscan Imaging Launches InSpecta Veterinary Imaging Device in US; Shares Hit 1.5-Year High
Optiscan Imaging (ASX:OIL) said it has launched InSpecta, its veterinary-first microscopic imaging device, in the US after successfully submitting its regulatory documents to the US Food and Drug Administration (FDA) Center for Veterinary Medicine, according to a Tuesday Australian bourse filing. The company said InSpecta creates a new in-house imaging capability for veterinary practices, supporting faster clinical insight, workflow efficiency, and potential new revenue opportunities. The launch means Optiscan has brought its first clinical device to market, creating a regulatory pathway that should support future product submissions, it added. The company's shares rose 11% in recent Tuesday trade and earlier hit their highest price since February 2025.
Optiscan Imaging (ASX:OIL) said it has launched InSpecta, its veterinary-first microscopic imaging device, in the US after successfully submitting its regulatory documents to the US Food and Drug Administration (FDA) Center for Veterinary Medicine, according to a Tuesday Australian bourse filing.
The company said InSpecta creates a new in-house imaging capability for veterinary practices, supporting faster clinical insight, workflow efficiency, and potential new revenue opportunities.
The launch means Optiscan has brought its first clinical device to market, creating a regulatory pathway that should support future product submissions, it added.
The company's shares rose 11% in recent Tuesday trade and earlier hit their highest price since February 2025.